Navigation Links
Watson Confirms Pataday™ Patent Challenge
Date:6/14/2011

PARSIPPANY, N.J., June 14, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%.  Watson's Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% is a generic version of Alcon, Inc.'s Pataday™ (olopatadine hydrochloride ophthalmic solution) 0.2%, which is indicated for the treatment of ocular itching associated with allergic conjunctivitis.

Alcon Research, Ltd., Alcon Pharmaceuticals, Ltd., and Kyowa Hakko Kirin Co., Ltd. filed suit against Watson on June 9, 2011 in the United States District Court for the Southern District of Indiana seeking to prevent Watson from commercializing its product prior to the expiration of U.S. Patent Nos. 5,641,805, 6,995,186, and 7,402,609.  Alcon's lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Watson's ANDA until October 29, 2013, or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.

For the twelve months ending April 30, 2011, Pataday had total U.S. sales of approximately $224 million according to IMS Health data.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the difficulty of predicting the timing or outcome of product development efforts, including FDA and other regulatory agency approvals and actions, if any; the difficulty of predicting the timing and outcome of the pending patent litigation; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on form 10-Q for the quarter ended March 31, 2011 and Watson's annual report on Form 10-K for the year ended December 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.  

Pataday™ (olopatadine hydrochloride ophthalmic solution) 2% is a trademark of Novartis AG. CONTACTS:Investors:Patty Eisenhaur(862) 621-8141Media:Charlie Mayr(862) 621-8030(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)


'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2017)... , Aug. 2, 2017 CaryRx, a next-generation ... day delivery service for patients in the Washington ... traditional retail pharmacy by providing delivery of medications through the ... for future delivery or delivered within one hour to any ... are excited to bring this invaluable service to ...
(Date:7/31/2017)... 7D Surgical, developer of ground breaking surgical navigation ... Surgical System to support its strategic sales plan in ... and Virginia.  7D Surgical has entered into an exclusive sales ... medical facilities within those markets. ... Spartan Medical Purchases ...
(Date:7/27/2017)... 2017  West Pharmaceutical Services, Inc. (NYSE: ... second-quarter 2017 and updated financial guidance for the full-year ... Highlights Reported net sales of $397.6 ... quarter. Net sales at constant currency (organic) grew by ... $0.51, compared to $0.60 in the prior-year quarter. Second-quarter ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... August 16, 2017 , ... ... their doors. They celebrate 30 years in business this year, and they’re marking ... inviting, tranquil space to serve their patients. , It stands to reason ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... ... Telehealth, Inc. has received a three-year grant totaling $975,000, renewing its funding from ... Health and Human Services. , This funding marks, the fourth time the HRSA ...
(Date:8/16/2017)... ... August 16, 2017 , ... SGNA ... endoscope after every reprocessing cycle, both between patient procedures and before storage, is ... Drying is as important to the prevention of disease transmission and nosocomial infection ...
(Date:8/16/2017)... Salt Lake City, Utah (PRWEB) , ... August 16, 2017 , ... ... its spot on the Inc 5000 list for the fourth consecutive year. ... the Inc. 5000 2017 list of the nation’s fastest growing companies. , ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... First ... United States, named Dr. Douglas J. Harrison, as the new Medical Director of its ... the new facility Medical Director of our Sienna Plantation location,” said Dr. Michael (Derek) ...
Breaking Medicine News(10 mins):